Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM65MEL)

Drug Name

LXS196 Drug Info

Synonyms

XXJXHXJWQSCNPX-UHFFFAOYSA-N; 1874276-76-2; LXS-196; NVP-LXS196; SCHEMBL17506262; CHEMBL3982723; LXS 196; BDBM251460; EX-A2690; BCP20781; ZINC584641445; CS-7529; HY-101569; US9452998, 9; 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]
Melanoma	2C30	Phase 1	[2]

Cross-matching ID

PubChem CID: 118873253
CAS Number: CAS 1874276-76-2
TTD Drug ID: DM65MEL

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Protein kinase C (PRKC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Synthetic hypericin	DMXU4ON	Virus infection	1A24-1D9Z	Phase 3	[3]
APH-0812	DM756GE	Human immunodeficiency virus-1 infection	1C62	Phase 2	[4]
CYCLOPLATAM	DMXR8WN	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
AEB07	DMJVN89	Transplant rejection	NE84	Phase 2	[6]
HO/03/03	DMA6HQJ	Diabetic foot ulcer	BD54	Phase 2	[7]
Bryostatin-1	DM1JOXY	Alzheimer disease	8A20	Phase 2	[8]
SAFINGOL	DMBGUDR	Psoriasis vulgaris	EA90	Phase 1	[9]
GCC-1290K	DMJ7WRI	Parkinson disease	8A00.0	Phase 1	[10]
AEB701	DM8I4G0	Melanoma	2C30	Phase 1	[11]
Tecadenoson	DM9T6MS	Atrial fibrillation	BC81.3	Discontinued in Phase 3	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein kinase C (PRKC)	TTYVX59	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03947385) Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8.
4	Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
5	Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73.
6	What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81.
7	WO patent application no. 2014,0853,81, Pharmaceutical combinations.
8	Bryostatin-1: a promising compound for neurological disorders. Front Pharmacol. 2023 Jun 7;14:1187411.
9	The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71.
10	Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
11	Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253.
12	Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63.